Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Other hematologic neoplasm 6Gynecologic 6Genitourinary 6Breast 6Gastrointestinal 5Lymphoid 3Head & Neck 3Tumor-Agnostic 2Dermatologic 2CNS 2Sarcoma 1Plasma cell 1Other solid neoplasm 1

Conditions

Smoldering Multiple Myeloma 1

Interventions

Dexamethasone 132Lenalidomide 85daratumumab 62Bortezomib 58carfilzomib 45Calcium Dobesilate 41pomalidomide 37Cyclophosphamide 32isatuximab 26belantamab mafodotin 23Specimen Handling 21Biopsy 21Magnetic Resonance Spectroscopy 18dexamethasone acetate 16dexamethasone 21-phosphate 16ixazomib 15auricularum 15Melphalan 15fludarabine 13selinexor 11iberdomide 11elotuzumab 11fludarabine phosphate 9X-Rays 8talquetamab 7venetoclax 6trametinib 6nirogacestat 6Whole-Body Irradiation 6Thalidomide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Observation × Plasma cell × Clear all
NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡